2021
Nasal Microbiota and Infectious Complications After Elective Surgical Procedures
Hsiao C, Paulson J, Singh S, Mongodin E, Carroll K, Fraser C, Rock P, Faraday N. Nasal Microbiota and Infectious Complications After Elective Surgical Procedures. JAMA Network Open 2021, 4: e218386. PMID: 33914049, PMCID: PMC8085724, DOI: 10.1001/jamanetworkopen.2021.8386.Peer-Reviewed Original ResearchMeSH KeywordsAgedBacteremiaCardiac Surgical ProceduresCase-Control StudiesCraniotomyElective Surgical ProceduresFemaleHumansMaleMicrobiotaMiddle AgedNosePneumoniaPostoperative ComplicationsRisk AssessmentRisk FactorsRNA, Ribosomal, 16SSpinal FusionStaphylococcus aureusSurgical Wound InfectionVascular Surgical ProceduresConceptsBaseline clinical characteristicsSurgical proceduresElective surgical proceduresInfectious complicationsInfectious outcomesPostoperative infectionClinical characteristicsComposite of surgical site infectionsNasal carriage of Staphylococcus aureusNasal microbiotaNo history of autoimmune diseaseCarriage of Staphylococcus aureusHistory of autoimmune diseaseProspective cohort of patientsNasal microbiomeTertiary care university hospitalOccurrence of postoperative infectionsImmune-modulating medicationsPostoperative infectious complicationsHigher oddsSurgical site infectionCohort of patientsIntracranial surgical proceduresAssociated with higher oddsNasal carriage
2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn L, Herrera A, Flowers C, Kamdar M, McMillan A, Hertzberg M, Assouline S, Kim T, Kim W, Ozcan M, Hirata J, Penuel E, Paulson J, Cheng J, Ku G, Matasar M. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal Of Clinical Oncology 2019, 38: 155-165. PMID: 31693429, PMCID: PMC7032881, DOI: 10.1200/jco.19.00172.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBiomarkers, TumorFemaleHumansImmunoconjugatesImmunohistochemistryLymphoma, Large B-Cell, DiffuseMaleMiddle AgedProgression-Free SurvivalSurvival RateConceptsProgression-free survivalLarge B-cell lymphomaPolatuzumab vedotinB-cell lymphomaCR rateOverall survivalPola-BRR/R DLBCLRefractory diffuse large B-cell lymphomaIRC-assessed progression-free survivalDiffuse large B-cell lymphomaB-cell receptor componentsSingle-arm cohortsDuration of responseCohort of patientsCox regression methodRisk of deathMedian OSSafety profileKaplan-MeierTreatment optionsB cellsPolatuzumabBendamustineDLBCL